AR080894A1 - Compuestos derivados de 2,8-diaza-espiro-[4,5]decano-1,7-diona, proceso para prepararlos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de la obesidad, dislipidemia y diabetes. - Google Patents

Compuestos derivados de 2,8-diaza-espiro-[4,5]decano-1,7-diona, proceso para prepararlos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de la obesidad, dislipidemia y diabetes.

Info

Publication number
AR080894A1
AR080894A1 ARP110101255A ARP110101255A AR080894A1 AR 080894 A1 AR080894 A1 AR 080894A1 AR P110101255 A ARP110101255 A AR P110101255A AR P110101255 A ARP110101255 A AR P110101255A AR 080894 A1 AR080894 A1 AR 080894A1
Authority
AR
Argentina
Prior art keywords
pyrimidyl
haloalkyl
espiro
decano
dislipidemia
Prior art date
Application number
ARP110101255A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR080894A1 publication Critical patent/AR080894A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Compuestos de la formula (1) en la que R1 es alquilo, cicloalquilo, haloalquilo, piperidinilo, piperazinilo, morfolinilo, imidazolilo, pirazolilo, triazolilo, tetrazolilo, oxazolilo, isoxazolilo, tiazolilo, fenilo, piridinilo, pirazinilo, pirimidilo o piridazinilo o en la que piperidinilo, piperazinilo, morfolinilo, imidazolilo, pirazolilo, triazolilo, tetrazolilo, oxazolilo, isoxazolilo, tiazolilo, fenilo, piridinilo, pirazinilo, pirimidilo y piridazinilo están sustituidos de una a tres veces por sustituyentes elegidos con independencia entre alquilo, cicloalquilo, cicloalquilalquilo, halogeno, haloalquilo, hidroxi, hidroxialquilo, alcoxi, alcoxialquilo, haloalcoxi e hidroxi-haloalquilo; R2 es fenilo, piridinilo, pirazinilo, pirimidilo o piridazinilo o en la que fenilo, piridinilo, pirazinilo, pirimidilo y piridazinilo están sustituidos de una a tres veces por sustituyentes elegidos con independencia entre alquilo, cicloalquilo, cicloalquilalquilo, halogeno, haloalquilo, hidroxi, hidroxialquilo, alcoxi, alcoxialquilo, haloalcoxi e hidroxi-haloalquilo; A es -(CH2)n-, -C(O)- o -S(O)2-; n es el numero cero, 1 o 2; o sus sales farmacéuticamente aceptables.
ARP110101255A 2010-04-15 2011-04-13 Compuestos derivados de 2,8-diaza-espiro-[4,5]decano-1,7-diona, proceso para prepararlos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de la obesidad, dislipidemia y diabetes. AR080894A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10160030 2010-04-15

Publications (1)

Publication Number Publication Date
AR080894A1 true AR080894A1 (es) 2012-05-16

Family

ID=44010146

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101255A AR080894A1 (es) 2010-04-15 2011-04-13 Compuestos derivados de 2,8-diaza-espiro-[4,5]decano-1,7-diona, proceso para prepararlos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de la obesidad, dislipidemia y diabetes.

Country Status (13)

Country Link
US (1) US8097634B2 (es)
EP (1) EP2558464B1 (es)
JP (1) JP5956423B2 (es)
KR (1) KR20130098153A (es)
CN (1) CN102844316B (es)
AR (1) AR080894A1 (es)
BR (1) BR112012026147A2 (es)
CA (1) CA2795101A1 (es)
ES (1) ES2490266T3 (es)
MX (1) MX2012010826A (es)
RU (1) RU2567395C2 (es)
TW (1) TW201202237A (es)
WO (1) WO2011128316A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389539B2 (en) * 2009-12-01 2013-03-05 Hoffman-La Roche Inc. Azacyclic derivatives
US8552024B2 (en) * 2010-08-13 2013-10-08 Hoffman-La Roche Inc. Azacyclic compounds
US8722721B2 (en) * 2011-03-16 2014-05-13 Hoffmann-La Roche Inc. SEC-hydroxycyclohexyl derivatives
US8703807B2 (en) * 2011-03-17 2014-04-22 Hoffmann-La Roche Inc. Azaspirodecanone compounds
US8809384B2 (en) * 2011-03-25 2014-08-19 Hoffmann-La Roche Inc. Azaspirodecanone compounds
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
CA2894281C (en) 2012-12-20 2021-04-20 Inception 2, Inc. Triazolone compounds and uses thereof
BR112015018087B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos
EP3041826A4 (en) 2013-09-06 2017-02-15 Inception 2, Inc. Triazolone compounds and uses thereof
SG11201900554YA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda modulators and methods of using same
CN109661398B (zh) 2016-08-01 2022-07-05 阿普廷伊克斯股份有限公司 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
US10918637B2 (en) 2016-08-01 2021-02-16 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
AU2017306152A1 (en) 2016-08-01 2019-01-31 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
BR112019001921A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores do receptor nmda de espiro-lactama e seus usos
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ571695A (en) * 2001-12-28 2010-02-26 Acadia Pharm Inc Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events
DE10247680B4 (de) * 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase
BRPI0607545A2 (pt) * 2005-02-15 2016-11-01 Novo Nordisk As composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
CN101115741A (zh) * 2005-02-15 2008-01-30 诺和诺德公司 3,4-二氢-1h-异喹啉-2-羧酸5-氨基吡啶-2-基酯
TW200804382A (en) 2005-12-05 2008-01-16 Incyte Corp Lactam compounds and methods of using the same
CN101336243A (zh) * 2005-12-05 2008-12-31 因塞特公司 内酰胺化合物和其使用方法
US8329904B2 (en) 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
US8440710B2 (en) * 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
US8389539B2 (en) * 2009-12-01 2013-03-05 Hoffman-La Roche Inc. Azacyclic derivatives
BR112013000249A2 (pt) * 2010-07-13 2016-05-24 Hoffmann La Roche novos compostos azacíclicos
US8552024B2 (en) * 2010-08-13 2013-10-08 Hoffman-La Roche Inc. Azacyclic compounds
US8722721B2 (en) * 2011-03-16 2014-05-13 Hoffmann-La Roche Inc. SEC-hydroxycyclohexyl derivatives
US8703807B2 (en) * 2011-03-17 2014-04-22 Hoffmann-La Roche Inc. Azaspirodecanone compounds
US8809384B2 (en) * 2011-03-25 2014-08-19 Hoffmann-La Roche Inc. Azaspirodecanone compounds

Also Published As

Publication number Publication date
RU2567395C2 (ru) 2015-11-10
JP5956423B2 (ja) 2016-07-27
CA2795101A1 (en) 2011-10-20
US8097634B2 (en) 2012-01-17
US20110257212A1 (en) 2011-10-20
HK1176607A1 (en) 2013-08-02
EP2558464A1 (en) 2013-02-20
CN102844316B (zh) 2015-02-25
BR112012026147A2 (pt) 2016-06-28
JP2013523859A (ja) 2013-06-17
CN102844316A (zh) 2012-12-26
EP2558464B1 (en) 2014-06-18
WO2011128316A1 (en) 2011-10-20
RU2012146875A (ru) 2014-05-20
MX2012010826A (es) 2012-10-10
TW201202237A (en) 2012-01-16
KR20130098153A (ko) 2013-09-04
ES2490266T3 (es) 2014-09-03

Similar Documents

Publication Publication Date Title
AR080894A1 (es) Compuestos derivados de 2,8-diaza-espiro-[4,5]decano-1,7-diona, proceso para prepararlos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de la obesidad, dislipidemia y diabetes.
MX339193B (es) Polimorfos y solvatos de clorhidrato de 4-[2-[[5-metil-1-(2-naftal enil)-1h-pirazol-3-il]oxi]etil]morfolina.
AR096543A1 (es) INHIBIDORES DE QUINASA PI3 d Y g SELECTIVOS DUALES
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
CY1121071T1 (el) Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων
CY1119707T1 (el) Ενωσεις διαρυλικου αμιδιου ως αναστολεις της κινασης
MX2013009957A (es) Agente de control de endoparasitos.
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
CR11119A (es) Derivados de indazol oxadiazol sustituidos para uso como agonistas esfingozina 1-fosfato (sip)
CY1119227T1 (el) Παραγωγα πυριδινης ως ηπιοι αναστολεις της rock
JO3452B1 (ar) بنزاميدات أمينو اريل مغاير كمثبطات كيناز
CU24315B1 (es) Nuevos derivados de 5-(2- {[3-(aminometil)-3,4-dihidroisoquin0-2(1 h)il] carbonil} fenil)-1 h-pirrol-3-carboxamida como inhibidores de bcl-2 y las composiciones farmacéuticas que los contienen
AR092289A1 (es) Derivados de aminoquinazolina y sus sales y metodos de uso
DOP2014000265A (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
UY33191A (es) Derivados de pirazina
MX2019012945A (es) Formas cristalinas de un compuesto inhibidor de jak.
CL2012000640A1 (es) Uso del compuesto n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina o su sal para el tratamiento de cancer refractario a tratamiento con un agente anti-cancer.
PH12012501027A1 (en) 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
CR20130145A (es) Moduladores del receptor gpr119 y el tratamieto de trastornos relacionados con este
AR076692A1 (es) Piperidinas sustituidas
AR082631A1 (es) Derivados de 2,8-diaza-espiro[4,5]decan-1-ona, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para tratar diabetes, obesidad, dislipemia y sindrome metabolico
AR085236A1 (es) Compuestos de benzodioxol-piperazina como moduladores de los receptores 5-hty d
AR073591A1 (es) Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4'-(trifluorometoxi)-[1,1'-bifenil]-3-carboxamida,composiciones farmaceuticas que las contienen,utiles para el tratamiento de carcinomas.
AR085909A1 (es) Derivados de azaespirodecanona, composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos para el tratamiento de diabetes, obesidad y enfermedades cardiovasculares, entre otras
AR082151A1 (es) Compuestos azaciclicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure